{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:38:03Z","timestamp":1781829483177,"version":"3.54.5"},"reference-count":23,"publisher":"FapUNIFESP (SciELO)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An. Bras. Dermatol."],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:p> BACKGROUND:  Actinic keratosis is a frequent lesion which occurs in sunlight exposed areas. Diclofenac sodium and 5-Fluorouracil are effective, non-invasive and easy-to-apply topical treatment options.    OBJECTIVES:  To assess and compare the effectiveness of 3% diclofenac sodium associated with 2.5% hyaluronic acid and of 5% 5-Fluorouracil for the treatment of actinic keratosis, as well as the patient's degree of satisfaction and tolerability.    METHODS: 28 patients with a clinical diagnosis of actinic keratosis were randomized to receive diclofenac sodium or 5-Fluorouracil and were clinically assessed before and after treatment as well as 8 weeks after the end of treatment. Modified versions of the Investigator and Patient Global Improvement Scores were used.    RESULTS:  The average number of lesions in the diclofenac sodium group before and after treatment was 13.6 and 6.6 (p&lt;0,001), respectively, while it was 17.4 and 3.15 (p&lt;0.001) in the 5-Fluorouracil group. There was a significant reduction in the number of lesions in the 5-Fluorouracil group in relation to the diclofenac sodium group (p&lt;0.001). To the non-blinded physician, there was a higher satisfactory therapeutic response in the 5-Fluorouracil group (p&lt;0.001); to the blinded physician, there was a higher satisfactory response in this same group, although not statistically significant (p=0.09). There was a high degree of satisfaction in both groups (73% in the diclofenac sodium group and 77% in the 5-Fluorouracil group; p=0.827). Regarding adverse effects, the diclofenac sodium group presented a higher degree of satisfaction (93.3% vs 38.4%; p=0.008). Erythema, edema, crusts and itching were significantly higher in the 5-Fluorouracil group.    CONCLUSION:  We concluded that 5-Fluorouracil was more effective; however, it showed lower tolerability than diclofenac sodium.<\/jats:p>","DOI":"10.1590\/abd1806-4841.20132083","type":"journal-article","created":{"date-parts":[[2013,11,25]],"date-time":"2013-11-25T13:35:43Z","timestamp":1385386543000},"page":"732-738","source":"Crossref","is-referenced-by-count":28,"title":["Comparative study of actinic keratosis treatment with 3% diclofenac sodium and 5% 5-fluorouracil"],"prefix":"10.1590","volume":"88","author":[{"given":"Majorie Mergen","family":"Segatto","sequence":"first","affiliation":[{"name":"Federal University of Health Sciences of Porto Alegre,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Ivan Torres","family":"Dornelles","sequence":"additional","affiliation":[{"name":"Health Secretariat,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera Bauer","family":"Silveira","sequence":"additional","affiliation":[{"name":"Health Secretariat,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela de Oliveira","family":"Frantz","sequence":"additional","affiliation":[{"name":",  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","series-title":"Fundamentos de dermatologia","author":"Ramos e Silva M","year":"2009","edition":"1 ed"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1067\/mjd.2000.103342","article-title":"Epidemiology of actinic keratoses and squamous cell carcinoma","volume":"42","author":"Salache SJ","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"ref3","first-page":"545","article-title":"Nosologic profile of dermatologic visits in Brazil","volume":"81","year":"2006","journal-title":"An Bras Dermatol"},{"key":"ref4","first-page":"S8","article-title":"A survey of office visits for actinic keratosis as reported by NAMCS, 1990-1999. National Ambulatory Medical Care Survey","volume":"70","author":"Gupta AK","year":"2002","journal-title":"Cutis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(88)91658-3","article-title":"Malignant transformation of solar keratoses to squamous cell carcinoma","volume":"1","author":"Marks R","year":"1988","journal-title":"Lancet"},{"key":"ref6","series-title":"Dermatology","author":"Bolognia JL","year":"2008","edition":"2nd ed"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1524-4725.1995.tb00141.x","article-title":"Solar keratosis: an evolving squamous cell carcinoma: Benign or malignant?","volume":"21","author":"Hurwitz RM","year":"1995","journal-title":"Dermatol Surg"},{"key":"ref8","first-page":"17","article-title":"Current treatments of actinic keratosis","volume":"5","author":"Gold MH","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"ref9","series-title":"Dermatopatologia pr\u00e1tica","author":"Rapini RP","year":"2007"},{"key":"ref10","first-page":"667","article-title":"Treatment options for actinic keratoses","volume":"76","author":"McIntyre WJ","year":"2007","journal-title":"Am Fam Physician"},{"key":"ref11","first-page":"273","article-title":"New and emerging topical approaches for actinic keratoses","volume":"72","author":"Del Rosso JQ","year":"2003","journal-title":"Cutis"},{"key":"ref12","first-page":"365","article-title":"Topical therapy for actinic keratoses, I: 5-fluorouracil and imiquimod","volume":"71","author":"Tutrone WD","year":"2003","journal-title":"Cutis"},{"key":"ref13","first-page":"599","article-title":"Guidelines for the management of actinic keratoses","volume":"16","author":"Stockfleth E","year":"2006","journal-title":"Eur J Dermatol"},{"key":"ref14","first-page":"373","article-title":"Topical therapy for actinic keratoses, II: Diclofenac, colchicine, and retinoids","volume":"71","author":"Tutrone WD","year":"2003","journal-title":"Cutis"},{"key":"ref15","first-page":"241","article-title":"What is the role of field-directed therapy in the treatment of actinic keratosis? Part 1: overview and investigational topical agents","volume":"89","author":"Berman B","year":"2012","journal-title":"Cutis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2133.2006.07692.x","article-title":"Guidelines for the management of actinic keratoses","volume":"156","author":"de Berker D","year":"2007","journal-title":"Br J Dermatol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2133.2007.08271.x","article-title":"A randomised study of topical imiquimod vs. topical 5-fluoracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up","volume":"157","author":"Krawtchenko N","year":"2007","journal-title":"Br J Dermatol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-4632.2009.04045.x","article-title":"Effectiveness of 5-fluorouracil treatment for actinic keratosis--a systematic review of randomized controlled trials","volume":"48","author":"Askew DA","year":"2009","journal-title":"Int J Dermatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1440-0960.2002.00635.x","article-title":"Topical diclofenac in hyaluronan gel for the treatment of solar keratoses","volume":"44","author":"Gebauer K","year":"2003","journal-title":"Australes J Dermatol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.4103\/0378-6323.27749","article-title":"Efficacy of 3% diclofenac gel for the treatment of actinic keratoses: A randomized, double-blind, placebo controlled study","volume":"72","author":"Fariba I","year":"2006","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref21","first-page":"156","article-title":"Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp","volume":"5","author":"Smith SR","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/09546630701818870","article-title":"Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis","volume":"19","author":"Kose O","year":"2008","journal-title":"J Dermatolog Treat"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2230.2010.03999.x","article-title":"Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses","volume":"36","author":"Akarsu S","year":"2011","journal-title":"Clin Exp Dermatol"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abd\/v88n5\/0365-0596-abd-88-05-0732.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:00:42Z","timestamp":1747666842000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0365-05962013000500732&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0365-05962013000500732"],"URL":"https:\/\/doi.org\/10.1590\/abd1806-4841.20132083","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}